Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Other Gross PP&E Adjustments (2016 - 2026)

Neurocrine Biosciences filings provide 15 years of Other Gross PP&E Adjustments readings, the most recent being -$247.3 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 22.79% to -$247.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$247.3 million, a 22.79% increase, with the full-year FY2025 number at -$247.3 million, up 22.79% from a year prior.
  • Other Gross PP&E Adjustments hit -$247.3 million in Q4 2025 for Neurocrine Biosciences, up from -$468.9 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $37.9 million in Q4 2022 to a low of -$502.2 million in Q1 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$97.4 million (2021), compared with a mean of -$182.1 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 280.0% in 2021 and later tumbled 608.63% in 2024.
  • Neurocrine Biosciences' Other Gross PP&E Adjustments stood at $13.3 million in 2021, then soared by 184.96% to $37.9 million in 2022, then crashed by 219.26% to -$45.2 million in 2023, then tumbled by 608.63% to -$320.3 million in 2024, then increased by 22.79% to -$247.3 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$247.3 million (Q4 2025), -$468.9 million (Q3 2025), and -$492.3 million (Q2 2025) per Business Quant data.